



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/612,482 | 07/02/2003 | Daniel David Lecloux | UC0213 US NA4 | 3485 |

23906 7590 10/18/2006

E I DU PONT DE NEMOURS AND COMPANY
LEGAL PATENT RECORDS CENTER
BARLEY MILL PLAZA 25/1128
4417 LANCASTER PIKE
WILMINGTON, DE 19805

EXAMINER

YAMNITZKY, MARIE ROSE

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1774

DATE MAILED: 10/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/612,482

Applicant(s)

LECLOUX ET AL.

Examiner

Marie R. Yamnitzky

Art Unit

1774

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 31 July 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3,4,12-15 and 23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,4,12-15 and 23 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1774

1. This Office action is in response to applicant's amendment filed December 06, 2005, which provides a replacement drawing sheet for sheet 18/25, amends claims 1, 4 and 15, and cancels claim 2.

This Office action is also in response to applicant's amendment filed July 31, 2006, which amends the specification.

Claims 1, 3, 4, 12-15 and 23 are pending.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

2. The objection to the disclosure for informalities as set forth in the Office action mailed September 07, 2005 is overcome by the replacement drawing sheet 18/25 and the amendment to the specification.

The rejection of claims 1, 3 and 23 under 35 U.S.C. 102(b) as anticipated by Adachi et al. in *Journal of Applied Physics* 90(10) is overcome by claim amendment.

The rejection of claim 4 under 35 U.S.C. 102(b) as anticipated by Adachi et al. as evidenced by Naka et al. or Redecker et al. is overcome by claim amendment.

3. Claims 13-15 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1774

Claims 13 and 14 stand rejected under 35 U.S.C. 112, second paragraph, for reasons of record in the Office action mailed September 07, 2005.

Formulae V(s) and V(ad) as set forth in claim 15 are incorrect. In formula V(s), each of the two phenyl groups should be pyridyl groups (compare to original Fig. 9S). In formula V(ad), the two lines on the phenyl rings at the bottom of the formula should be bonds to "Br" (compare to original Fig. 9AD).

The limitations of claim 23 are not clear as dependent from claim 2, which has been cancelled. In line 1 of claim 23, "1-4 and 12-15" should read --1, 3, 4 and 12-15--.

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 1, 3, 4 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Adachi et al. in *Journal of Applied Physics* 90(10), pp. 5048-5051 (Nov. 15, 2001) in view of Egusa et al. (US 5,294,810).

Adachi et al. disclose organic light emitting devices comprising, in the order listed, an anode, a light emitting layer comprising (ppy)₂Ir(acac), which is a cyclometalated complex of a transition metal, an electron transport layer consisting of Alq₃, and a cathode.

Figure 6 on page 5051 provides energy diagrams for the devices. As one of ordinary skill in the art would recognize, while the LUMO and HOMO levels are shown as positive values in the figure, they are actually negative values relative to the vacuum level. The cyclometalated complex in the prior art devices has a LUMO of -3.0eV and a HOMO of -5.6eV , the electron transport layer has a LUMO of -3.3eV and a HOMO of -6.0eV , and the cathode has a work function of -3.7eV . Thus, in the prior art devices, $E_1-E_3 = 0.4\text{eV}$, $E_1-E_2 = -0.3\text{eV}$ and $E_4-E_5 = 0.4\text{eV}$, meeting provisos (1) and (3) as set forth in present claim 1 and proviso (3) as further limited by present claim 3.

The electron transport layer in Adachi's devices consists of Alq_3 , and therefore inherently meets the electron mobility limitation set forth in present claim 4. Alq_3 has an electron mobility that is greater than the lower limit set in claim 4 (as evidenced by art previously made of record).

Present claim 1 requires E_1-E_2 to be at least slightly more than 0, whereas E_1-E_2 is slightly less than 0 in Adachi's devices. Adachi's devices can be expected to have a slight barrier to flow of electrons from the electron transport layer/material into the light emitting layer and cyclometallated complex of a transition metal. The E_1-E_2 relationship required by claim 1 is not expected to provide any barrier to flow of electrons from the electron transport and/or anti-quenching layer to the cyclometalated complex per se of the photoactive layer. (The examiner notes that since the photoactive layer may comprise components other than the cyclometalated complex that will affect the LUMO of the layer, the LUMO of the photoactive layer is not necessarily the same as the LUMO of the cyclometalated complex of a transition metal.)

The relative LUMO levels of the electron transporting layer and the cyclometalated complex in Adachi's devices are similar to that depicted for layers O₁ and O₂, respectively, in Fig. 18 and described in columns 19 and 20 of the Egusa patent. The relative LUMO levels of the electron transporting layer and the cyclometalated complex for the device of present claim 1 are similar to that depicted for layers O₁ and O₃, respectively, in Fig. 2 and described in column 6 of the Egusa patent.

It would have been obvious to one of ordinary skill in the art at the time of the invention, having knowledge in the art such as knowledge of the teachings of Egusa, that different combinations of light emissive materials and electron transporting materials could be used to alter the ability of electrons to traverse from the cathode into the light emissive layer/materials, and thus alter device performance characteristics. One of ordinary skill in the art at the time of the invention would have reasonably expected, for example, that lowering or eliminating a barrier to flow of electrons from an electron transporting layer into a light emissive material would lower the operating voltage for the device. It would have been within the level of ordinary skill of a worker in the art at the time of the invention to determine suitable and optimal combinations of electron transporting materials and light emissive materials so as to optimize device performance. One of ordinary skill in the art would have been motivated to utilize combinations of materials providing $E_1 - E_2 > 0$ in order to improve the flow of electrons into the light emissive layer.

6. Claims 1, 3, 4, 12 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Li et al. (US 6,723,445 B2) in view of Egusa et al. (US 5,294,810).

Li et al. teach that quinoxaline derivatives can be used to form an electron injection/transport layer in EL devices, and that the luminescent material in the emissive layer of the device may be triplet emitter such as Ir(ppy)₃, which is a cyclometalated complex of a transition metal. For example, see Fig. 9, 10 and 11, and Examples 6 and 7 in columns 8 and 9.

Li et al. do not explicitly limit the relationship between the work function of the cathode and the LUMO and HOMO energy levels of the quinoxaline-containing layer and the luminescent material so as to meet present provisos (1)-(3).

Provisos (1)-(3) cover a variety of energy level relationships described in the Egusa patent. The relative LUMO levels of the electron transporting layer and the cyclometalated complex for the device of present claim 1 are similar to that depicted for layers O₁ and O₃, respectively, in Fig. 2 and described in column 6 of the Egusa patent. The relative HOMO levels of the electron transporting layer and the cyclometalated complex for the device of present claim 3 are similar to that depicted for layers O₁ and O₃, respectively, in Fig. 2 and described in column 6 of the Egusa patent.

It would have been obvious to one of ordinary skill in the art at the time of the invention, having knowledge in the art such as knowledge of the teachings of Egusa, that different combinations of light emissive materials and electron transporting materials could be used to alter the ability of electrons to traverse from the cathode into the light emissive layer/materials, and thus alter device performance characteristics. One of ordinary skill in the art at the time of

the invention would have reasonably expected, for example, that lowering or eliminating a barrier to flow of electrons from an electron transporting layer into a light emissive material would lower the operating voltage for the device. One of ordinary skill in the art also would have known that the relationship between the work function of the cathode and the LUMO of the electron transporting layer affects the turn-on voltage of the device and the flow of electrons from the cathode to the light emissive layer, and the relationship between the HOMO of the electron transporting layer and the HOMO of the light emissive material affects the flow of holes. It would have been within the level of ordinary skill of a worker in the art at the time of the invention to determine suitable and optimal combinations of cathode materials, electron transporting materials and light emissive materials so as to optimize device performance. One of ordinary skill in the art would have been motivated to utilize combinations of materials providing $E_1 - E_2 > 0$ in order to improve the flow of electrons into the light emissive layer. Regarding claim 3, one of ordinary skill in the art would have been motivated to utilize combinations of materials providing $E_4 - E_5 > 0$ in order to prevent the flow of holes out of the light emissive layer into the electron transporting layer.

With respect to present claim 4, Li et al. teach that the quinoxaline derivatives have good electron affinity, and the quinoxaline derivative utilized in Li's Examples 6 and 7 is said to have better electron injection and transporting properties than Alq_3 . Alq_3 has an electron mobility higher than the lower limit set forth in claim 4. Since the quinoxaline derivative in Li's Examples 6 and 7 has better electron injection and transporting properties than Alq_3 , it is

reasonable to expect that the quinoxaline derivative has an electron mobility higher than the lower limit set forth in claim 4.

7. Claims 1, 3, 4, 12-14 and 23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kamatani et al. (US 2002/0135292 A1) in view of Li et al. (US 6,723,445 B2) and Egusa et al. (US 5,294,810).

Kamatani et al. disclose the use quinoxaline derivatives in electron injection and/or transport layers in EL devices. For example, see paragraphs [0079]-[0087]. See the various compounds defined in Tables 5, 6, 7, 14 and 15 in which at least one of A and B is a_1 or a_2 , with the formulae for a_1 and a_2 shown in Table 1 on page 5. Many of these compounds meet the limitations of the quinoxaline derivative of Formula V in present claims 13 and 14. Kamatani et al. teach various materials that may be used in the luminescence (photoactive) layer, but do not explicitly teach using a cyclometalated complex of a transition metal in the luminescence layer.

Li et al. teach that quinoxaline derivatives can be used to form an electron injection/transport layer in EL devices, and that the luminescent material in the emissive layer of the device may be triplet emitter such as Ir(ppy)_3 , which is a cyclometalated complex of a transition metal. For example, see Fig. 9, 10 and 11, and Examples 6 and 7 in columns 8 and 9.

It would have been an obvious modification to one of ordinary skill in the art at the time of the invention, having knowledge of the teachings of Li et al., to utilize known triplet emitters such as Ir(ppy)_3 , in the luminescence layer of Kamatani's device. It was known in the art at the time of the invention that EL device efficiency can be improved by using a triplet emitter and,

based on Li's disclosure, one of ordinary skill in the art would have reasonably expected that Kamatani's quinoxaline derivatives could be used in an electron injection/transport layer in a device utilizing a triplet emitter such as Ir(ppy)₃ in the luminescence layer.

Neither Kamatani et al. nor Li et al. explicitly limit the relationship between the work function of the cathode and the LUMO and HOMO energy levels of the quinoxaline-containing layer and the luminescent material so as to meet present provisos (1)-(3).

Provisos (1)-(3) cover a variety of energy level relationships described in the Egusa patent. The relative LUMO levels of the electron transporting layer and the cyclometalated complex for the device of present claim 1 are similar to that depicted for layers O₁ and O₃, respectively, in Fig. 2 and described in column 6 of the Egusa patent. The relative HOMO levels of the electron transporting layer and the cyclometalated complex for the device of present claim 3 are similar to that depicted for layers O₁ and O₃, respectively, in Fig. 2 and described in column 6 of the Egusa patent.

It would have been obvious to one of ordinary skill in the art at the time of the invention, having knowledge in the art such as knowledge of the teachings of Egusa, that different combinations of light emissive materials and electron transporting materials could be used to alter the ability of electrons to traverse from the cathode into the light emissive layer/materials, and thus alter device performance characteristics. One of ordinary skill in the art at the time of the invention would have reasonably expected, for example, that lowering or eliminating a barrier to flow of electrons from an electron transporting layer into a light emissive material would lower the operating voltage for the device. One of ordinary skill in the art also would

have known that the relationship between the work function of the cathode and the LUMO of the electron transporting layer affects the turn-on voltage of the device and the flow of electrons from the cathode to the light emissive layer, and the relationship between the HOMO of the electron transporting layer and the HOMO of the light emissive material affects the flow of holes. It would have been within the level of ordinary skill of a worker in the art at the time of the invention to determine suitable and optimal combinations of cathode materials, electron transporting materials and light emissive materials so as to optimize device performance. One of ordinary skill in the art would have been motivated to utilize combinations of materials providing $E_1 - E_2 > 0$ in order to improve the flow of electrons into the light-emissive layer. Regarding claim 3, one of ordinary skill in the art would have been motivated to utilize combinations of materials providing $E_4 - E_5 > 0$ in order to prevent the flow of holes out of the light-emissive layer into the electron-transporting layer.

With respect to present claim 4, Kamatani et al. teach that the chemical structure of the compounds can be optimized to optimize electron mobility (see paragraph [0051]). Alq₃, a material known in the art for its electron transporting capability, has an electron mobility higher than the lower limit set forth in claim 4. It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention, to make and use quinoxaline derivatives as electron transporting materials having electron mobilities comparable to, or better than, conventional electron transporting materials such as Alq₃.

Art Unit: 1774

8. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

9. Claims 1, 3, 4, 12-15 and 23 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 42-61 of copending Application No. 10/612,704. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims encompass an electronic device such as a light-emitting diode, a light-emitting electrochemical cell, or a photodetector, wherein the electronic device comprises a photoactive layer and a second layer comprising a quinoxaline derivative.

The quinoxaline derivative required by copending claim 42 is the same as the quinoxaline derivative required by present claim 13, and copending claim 43 requires a subset of the

quinoxaline derivatives required by present claim 14. Copending claim 50 limits the quinoxaline derivative to 32 specific compounds; 29 of the 31 specific compounds represented by the formulae set forth in present claim 15 are the same as 29 of the 32 specific compounds represented by the formulae referenced in copending claim 50. (Upon correction of the errors noted in present formulae V(s) and V(ad) in claim 15, all 31 of the specific compounds set forth in claim 15 will be within the scope of the 32 specific compounds of copending claim 50.)

The copending claims do not require the photoactive layer to comprise a cyclometalated complex of a transition metal complex and do not limit the work function, LUMO and HOMO energy levels as in present provisos (1)-(3), but it would have been within the level of ordinary skill of a worker in the art at the time of the invention to select suitable materials from known materials for use in the photoactive layer of the copending device claims, and to optimize device performance based on comparative energy levels of the components of the device.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

10. Applicant's arguments filed December 06, 2005 have been fully considered as applicable to the rejections set forth in this action, but they are not persuasive.

With respect to the rejection of claims 13 and 14 under 35 U.S.C. 112, second paragraph, applicant argues that the terms "alkylenearyl" and "alkyleneheteroaryl" are the same as "arylalkylene" and "heteroarylalkylene", respectively. This equivalency is not clear in the application as originally filed, and the specification does not define "alkylenearyl" and

“alkyleneheteroaryl”. The specification does define “arylalkylene” and “heteroarylalkylene”.

The examiner suggests that claim 13 be amended to use the terminology defined in the specification.

With respect to the question regarding $n=0$, applicant states that “0” is explicitly listed when applicable, and that “n” cannot be 0. This does not alter the fact that the term “integer”, by conventional definition, encompasses 0. The examiner suggests that the definition of “n” in claim 13 be amended to read --n is an integer of at least 1-- (or similar language).

With respect to the various rejections under 35 U.S.C. 103(a), references to layer “O₃” in Egusa’s device of Fig. 18 have been changed to “O₁”, and references to layer “O₂” in Egusa’s device of Fig. 2 have been changed to “O₁”. Layer “O₁” in the devices of Egusa’s Fig. 2 and Fig. 18 is an electron transport layer. Layer “O₃” in the device of Egusa’s Fig. 2 and layer “O₂” in the device of Egusa’s Fig. 18 are light emitting (photoactive) layers.

While Egusa does not favor one embodiment over the other, Egusa’s teachings demonstrate that one of ordinary skill in the art at the time of the invention understands how the relationships between LUMO and HOMO levels of different components of a light emitting device and the work functions of the electrodes affect device performance.

Further with respect to the rejections based on Kamatani et al. in view of Li et al. and Egusa et al., applicant argues that Kamatani does not disclose the quinoxaline derivatives of applicant’s claim 15. The examiner agrees. Claim 15 was not, and is not, included in the rejection based on Kamatani et al. (Claim 15 was, and is, rejected only under 35 U.S.C. 112, second paragraph, and on the grounds of provisional obviousness-type double patenting.)

Art Unit: 1774

With respect to the provisional obviousness-type double patenting rejection, applicant argues that the '704 application is not available as a reference against the present application since the present application and the '704 application claim priority of the same provisional application and have the same filing date. The claims for priority and the filing dates of the two applications do not preclude an obviousness-type double patenting rejection based on the '704 application. The claims for priority and the filing dates of the two applications only preclude the use of the '704 application as prior art under 35 U.S.C 102 and 35 U.S.C. 103.

11. Miscellaneous:

In claim 15, the period should be moved from the end of line 2 to after the last formula.

12. Any inquiry concerning this communication should be directed to Marie R. Yamnitzky at telephone number (571) 272-1531. The examiner works a flexible schedule but can generally be reached at this number from 6:30 a.m. to 4:00 p.m. Monday, Tuesday, Thursday and Friday, and every other Wednesday from 6:30 a.m. to 3:00 p.m.

The current fax number for all official faxes is (571) 273-8300. (Unofficial faxes to be sent directly to examiner Yamnitzky can be sent to (571) 273-1531.)

MRY
October 16, 2006



MARIE YAMNITZKY
PRIMARY EXAMINER

1774